🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

249 results for “ISTA” Clear

  1. PH94B

    Vistagen Therapeutics

    Adjustment Disorder With Anxious Mood

    phase 2 small molecule completed

    1 trial

  2. Pembrolizumab

    United Therapeutics Europe Ltd

    Castration-resistant Prostate Cancer

    phase 2 small molecule active

    1 trial

  3. Pevonedistat

    Takeda Pharmaceuticals International AG

    Myelodysplastic Syndromes (MDS)

    phase 2 small molecule terminated

    1 trial

  4. Pevonedistat

    Takeda Pharmaceuticals International AG

    Acute Myeloid Leukemia (AML)

    phase 2 small molecule completed

    2 trials

  5. Phase I/II First-In-Human open-label trial to assess safety and efficacy of STX-241 in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) resistant to EGFR tyrosine kinase inhibitors (TKIs)

    Pierre Fabre Medicament

    locally advanced or metastatic non-small cell lung cancer (NSCLC) resistant to EGFR tyrosine kinase inhibitors (TKIs)

    phase 2 other active

    1 trial

  6. Placebo

    Vistagen Therapeutics

    Healthy

    phase 2 small molecule completed

    1 trial

  7. Placebo to match LY3848575

    Eli Lilly Co.

    Neuropathic Pain; Distal Sensory Polyneuropathy

    phase 2 small molecule active

    1 trial

  8. Pluvicto 1 000 MBq/mL solution for injection/infusion, Locametz 25 micrograms kit for radiopharmaceutical preparation

    Novartis Ophthalmics Europe

    Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) with moderate and severe renal impairment and with normal renal function.

    phase 2 small molecule active

    1 trial

  9. Psilocybin

    COGNITION THERAPEUTICS INC

    Treatment Resistant Depression

    phase 2 small molecule completed

    1 trial

  10. Psilocybin

    Compass Therapeutics

    Treatment-Resistant Major Depressive Disorder

    phase 2 small molecule terminated

    1 trial

  11. Psilocybin 25 mg Capsules, TRITTICO 60 mg/ml gocce orali, soluzione, PCB2 (Placebo of psilocybin 25mg), Trazodone placebo (pharmaceutical master preparation prepared according to the Good Pharmacy Practice)

    Pari Pharma GmbH

    Treatment-resistant depression

    phase 2 small molecule active

    1 trial

  12. QL1706

    China SXT Pharmaceuticals

    Platinum-resistant Recurrent Ovarian Cancer

    phase 2 small molecule active

    1 trial

  13. REGN15505

    Regeneron UK Limited

    Metastatic Castration-Resistant Prostate Cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  14. REGN4336

    Regeneron UK Limited

    Metastatic Castration-resistant Prostate Cancer

    phase 2 small molecule active

    1 trial

  15. REGN5678

    Regeneron UK Limited

    Metastatic Castration-Resistant Prostate Cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  16. SNS-101 (anti-VISTA)

    Regeneron UK Limited

    Solid Tumor, Adult

    phase 2 small molecule active

    1 trial

  17. SRF617

    Arcus Biosciences

    Metastatic Castration-resistant Prostate Cancer

    phase 2 small molecule terminated

    1 trial

  18. SSGJ-707

    Sunshine Biopharma

    Advanced/recurrent Endometrial Cancer and Platinum-resistant Ovarian Cancer

    phase 2 small molecule active

    1 trial

  19. SX-682

    United Therapeutics Europe Ltd

    Metastatic Castrate-Resistant Prostate Cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  20. TAK-653

    Takeda Pharmaceuticals International AG

    Treatment-Resistant Depression

    phase 2 small molecule terminated

    1 trial

  21. TD001

    Ology Bioservices Ireland LTD

    Metastatic castration-resistant prostate cancer

    phase 2 small molecule active

    1 trial

  22. TECLISTAMAB, TECLISTAMAB

    Fondazione Telethon ETS

    refractory/relapsed multiple myeloma

    phase 2 small molecule active

    1 trial

  23. TOCILIZUMAB , SECUKINUMAB , ANAKINRA , ADALIMUMAB , RITUXIMAB, USTEKINUMAB

    Pari Pharma GmbH

    Patients displaying a non-classified, severe and resistant inflammatory disease

    phase 2 small molecule active

    1 trial

  24. TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone

    China SXT Pharmaceuticals

    Prostatic Neoplasms, Castration-Resistant

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources